Nanaimo-based Tilray announced the launch of a new brand of medical cannabis products.
According to a press release earlier this month, Symbios was launched “to complement the company’s existing medical brand portfolio in Canada” with flowers, oils and pre-rolls at a “better price” for patient health and wellness needs.
Tilray also announced a line of new topical medicinal cannabis topical products under the brand name Aphria that are designed to combat inflammatory joint disease when applied to the skin.
“Symbios and our new Aphria topical treatments are exciting new additions to our medical portfolio in Canada, offering our patients a wider choice of unique product formats to suit their needs and preferences,” said Jim Meiers, President of Tilray Canada, in the press release. “Our industry is only in the early stages of developing and bringing to market cannabinoid medicine options that meet patient needs. We are committed to building our leadership position in Canada now and in the future. “
Tilray and Aphria announced a merger of the two companies in December and will now market the companies’ cannabis brands under the Tilray name.
ALSO READ: The merger makes Tilray, based in Nanaimo, the world’s largest cannabis company
Irwin D. Simon, Tilray chief executive officer, said medical cannabis innovation and patient care are at the heart of Tilray’s new business and global growth strategy. “We are looking ahead and continuing our focus on building the momentum of our three medical brands – Symbios, Aphria and Tilray – while meeting the huge and growing demand for new, high-quality cannabis products that promote health, wellbeing and wellbeing.” said.
Like us on Facebook and follow us on Twitter